论文部分内容阅读
对于肠道炎症的治疗,5-氨基水杨酸(5-ASA)是水杨酸偶氮磺胺吡啶(SASP)的活性成分的概念已日益得到重视,并制备了5-ASA的肠道内缓释制剂(Pentasa)。作者对18例(男5例、女13例,年龄16～63岁,平均33岁)其他药物治疗无效的活动性克罗恩氏病,口服5-ASA以观察其临床效果。18例均有小肠病变,其中10例兼有结肠损害,7例曾接受小肠、结肠等各种手术。5-ASA剂量为500mg,每日3次,治疗6周。治疗前2周停用其它药物治疗,治疗后2周进行总结。经6周治疗后,13例(72％)病情改善,2例(11％)无变化,3例
For the treatment of intestinal inflammation, the concept that 5-aminosalicylic acid (5-ASA) is the active ingredient of salicylazosulfapyridine (SASP) has received increasing attention and prepared for sustained release of 5-ASA Formulation (Pentasa). The authors of 18 cases (5 males and 13 females, aged 16 to 63 years, mean 33 years) other active drug treatment of Crohn’s disease, oral 5-ASA to observe its clinical effect. Eighteen cases had small bowel lesions, of which 10 cases both colon damage, 7 cases had received small intestine, colon and other surgery. The 5-ASA dose was 500 mg three times daily for 6 weeks. Two weeks before treatment, other drugs were discontinued and 2 weeks after treatment. After 6 weeks of treatment, 13 (72%) patients had improved disease, 2 (11%) had no change, and 3